Scinai Immunotherapeutics (NASDAQ:SCNI) vs. Phathom Pharmaceuticals (NASDAQ:PHAT) Financial Comparison

Scinai Immunotherapeutics (NASDAQ:SCNI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Valuation and Earnings

This table compares Scinai Immunotherapeutics and Phathom Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$660,000.00	4.74	$4.80 million	($9.57)	-0.10
Phathom Pharmaceuticals	$147.19 million	6.63	-$334.33 million	($3.82)	-3.58

Scinai Immunotherapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Scinai Immunotherapeutics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Insider & Institutional Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Scinai Immunotherapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Phathom Pharmaceuticals	-186.53%	N/A	-79.41%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Scinai Immunotherapeutics and Phathom Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Phathom Pharmaceuticals	1	2	5	1	2.67

Phathom Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 53.62%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Scinai Immunotherapeutics.

Summary

Phathom Pharmaceuticals beats Scinai Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.